Hua Medicine (Shanghai) Ltd.
HKSE 2552.HK
Hua Medicine (Shanghai) Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -13.80%
-
Hua Medicine (Shanghai) Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -21.42%, a 46.96% change year over year.
-
Hua Medicine (Shanghai) Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -40.38%, a -25.12% change year over year.
-
Hua Medicine (Shanghai) Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -32.27%, a 17.14% change year over year.
-
Hua Medicine (Shanghai) Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -38.94%.
| Date | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio | Return on Common Equity |
|---|
Don’t Miss A Beat
| CEO | Dr. Li Chen Ph.D. |
| IPO Date | Sept. 14, 2018 |
| Location | China |
| Headquarters | Building A |
| Employees | 172 |
| Sector | Healthcare |
| Industries | |
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
Past 5 years
USD 0.51
USD 4.20
USD 0.29
USD 1.36
StockViz Staff
February 4, 2025
Any question? Send us an email